How many diseases are colorectal cancer?

Gastroenterology Research and Practice

Volumn , Issue , 2012, Pages

  Greystoke, A ^a,b   Mullamitha, S A ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; COLON; COLORECTAL CANCER; DISEASE CLASSIFICATION; GENE MUTATION; GENETIC HETEROGENEITY; HISTOLOGY; HISTOPATHOLOGIC SKIN REACTION; HUMAN; NONHUMAN; ONCOGENE; RECTUM; REVIEW; TREATMENT RESPONSE;

EID: 84866980337     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2012/564741     Document Type: Review

References (110)

1. Jain V. K., Hawkes E. A., Cunningham D., Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer. Clinical Colorectal Cancer 2011 10 245 257
2. Barton S., Swanton C., Recent developments in treatment stratification for metastatic breast cancer. Drugs 2011 71 2099 2113
3. Curtis C., Shah S. P., Chin S. F., The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012 486 7403 346 352
4. Hill B. T., Sweetenham J., Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. Leukemia & Lymphoma 2012 53 763 769
5. Custodio A., Méndez M., Provencio M., Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treatment Reviews 2012 38 1 36 53 2-s2.0-79955788709 10.1016/j.ctrv.2011. 04.001
6. Ogino S., Chan A. T., Fuchs C. S., Giovannucci E., Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011 60 3 397 411 2-s2.0-79851511414 10.1136/gut.2010.217182
7. Quirke P., Steele R., Monson J., Grieve R., Khanna S., Couture J., O'Callaghan C., Myint A. S., Bessell E., Thompson L. C., Parmar M., Stephens R. J., Sebag-Montefiore D., Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. The Lancet 2009 373 9666 821 828 2-s2.0-61349086080 10.1016/S0140-6736(09)60485-2
8. Köckerling F., Reymond M. A., Altendorf-Hofmann A., Dworak O., Hohenberger W., Influence of surgery on metachronous distant metastases and survival in rectal cancer. Journal of Clinical Oncology 1998 16 1 324 329 2-s2.0-0343573267 (Pubitemid 28041616)
9. Van Gijn W., Marijnen C. A. M., Nagtegaal I. D., Kranenbarg E. M. K., Putter H., Wiggers T., Rutten H. J. T., Påhlman L., Glimelius B., Van de Velde C. J. H., Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. The Lancet Oncology 2011 12 6 575 582 2-s2.0-79957502537 10.1016/S1470-2045(11)70097-3
10. Ceelen W. P., Van Nieuwenhove Y., Fierens K., Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database of Systematic Reviews 2009 124 12 2966 2972 2-s2.0-62449296925
11. André T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., Tabah-Fisch I., De Gramont A., Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. The New England Journal of Medicine 2004 350 23 2343 2351 2-s2.0-2542615200 10.1056/NEJMoa032709 (Pubitemid 38702845)
12. Yamauchi M., Morikawa T., Kuchiba A., Imamura Y., Qian Z. R., Nishihara R., Liao X., Waldron L., Hoshida Y., Huttenhower C., Chan A. T., Giovannucci E., Fuchs C., Ogino S., Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012 61 6 847 854
13. Adam R., Haller D. G., Poston G., Raoul J. L., Spano J. P., Tabernero J., van Cutsem E., Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the international congress on anti-cancer treatment (ICACT) 2009. Annals of Oncology 2010 21 8 1579 1584 2-s2.0-77955254992 10.1093/annonc/mdq043
14. Seymour M. T., Maughan T. S., Ledermann J. A., Topham C., James R., Gwyther S. J., Smith D. B., Shepherd S., Maraveyas A., Ferry D. R., Meade A. M., Thompson L., Griffiths G. O., Parmar M. K., Stephens R. J., Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007 370 9582 143 152 2-s2.0-34447255724 10.1016/S0140-6736(07)61087-3 (Pubitemid 47042894)
15. Gervaz P., Bucher P., Morel P., Two colons-two cancers: paradigm shift and clinical implications. Journal of Surgical Oncology 2004 88 4 261 266 2-s2.0-10044255290 10.1002/jso.20156 (Pubitemid 39601269)
16. Chauvenet M., Cottet V., Lepage C., Jooste V., Faivre J., Bouvier A. M., Trends in colorectal cancer incidence: a period and birth-cohort analysis in a well-defined French population. BMC Cancer 2011 11, article 282 2-s2.0-79959682989 10.1186/1471-2407-11-282
17. Larsen I. K., Bray F., Trends in colorectal cancer incidence in Norway 19622006: an interpretation of the temporal patterns by anatomic subsite. International Journal of Cancer 2010 126 3 721 732 2-s2.0-73449102188 10.1002/ijc.24839
18. Shah A. B., Sarfati D., Blakely T., Atkinson J., Dennett E. R., Trends in colorectal cancer incidence rates in New Zealand, 19812004. ANZ Journal of Surgery 2012 82 258 264
19. Siegel R. L., Ward E. M., Jemal A., Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 19922008. Cancer Epidemiology, Biomarkers & Prevention 2012 21 411 416
20. Derwinger K., Gustavsson B., Variations in demography and prognosis by colon cancer location. Anticancer Research 2011 31 6 2347 2350 2-s2.0-79960457625
21. Weiss J. M., Pfau P. R., O'Connor E. S., King J., LoConte N., Kennedy G., Smith M. A., Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results-Medicare data. Journal of Clinical Oncology 2011 29 4401 4409
22. Lagergren J., Ye W., Ekbom A., Intestinal cancer after cholecystectomy: is bile involved in carcinogenesis? Gastroenterology 2001 121 3 542 547 2-s2.0-0034834657 (Pubitemid 32822568)
23. Renehan A. G., Tyson M., Egger M., Heller R. F., Zwahlen M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. The Lancet 2008 371 9612 569 578 2-s2.0-38949108241 10.1016/S0140-6736(08)60269-X (Pubitemid 351232031)
24. Wong V. W. S., Wong G. L. H., Tsang S. W. C., Fan T., Chu W. C. W., Woo J., Chan A. W. H., Choi P. C. L., Chim A. M. L., Lau J. Y. W., Chan F. K. L., Sung J. J. Y., Chan H. L. Y., High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011 60 6 829 836 2-s2.0-79955804203 10.1136/gut.2011.237974
25. Sjo O. H., Berg M., Merok M. A., Kolberg M., Svindland A., Lothe R. A., Nesbakken A., Peritoneal carcinomatosis of colon cancer origin: highest incidence in women and in patients with right-sided tumors. Journal of Surgical Oncology 2011 104 7 792 797 2-s2.0-79955555289 10.1002/jso.21959
26. Hemminki K., Santi I., Weires M., Thomsen H., Sundquist J., Bermejo J. L., Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer 2010 10, article 688 2-s2.0-78650301501 10.1186/1471-2407-10-688
27. Edge S. B., Compton C. C., The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of Surgical Oncology 2010 17 6 1471 1474 2-s2.0-77954818058 10.1245/s10434-010- 0985-4
28. Bosman F. T., Carneiro F., Hruban R. H., Theise N. D., WHO Classification of Tumours of the Digestive System 2010 4th WHO Press
29. Verhulst J., Ferdinande L., Demetter P., Ceelen W., Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis. Journal of Clinical Pathology 2012 65 5 381 388
30. Catalano V., Loupakis F., Graziano F., Torresi U., Bisonni R., Mari D., Fornaro L., Baldelli A. M., Giordani P., Rossi D., Alessandroni P., Giustini L., Silva R. R., Falcone A., D'Emidio S., Fedeli S. L., Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. British Journal of Cancer 2009 100 6 881 887 2-s2.0-62549089251 10.1038/sj.bjc.6604955
31. Morikawa T., Kuchiba A., Qian Z. R., Mino-Kenudson M., Hornick J. L., Yamauchi M., Imamura Y., Liao X., Nishihara R., Meyerhardt J. A., Fuchs C. S., Ogino S., Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. The Annals of Surgical Oncology 2012 19 6 1944 1953
32. Zlobec I., Molinari F., Martin V., Mazzucchelli L., Saletti P., Trezzi R., de Dosso S., Vlajnic T., Frattini M., Lugli A., Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World Journal of Gastroenterology 2010 16 38 4823 4831 2-s2.0-78049495404 10.3748/wjg.v16.i38.4823
33. Fearon E. R., Vogelstein B., A genetic model for colorectal tumorigenesis. Cell 1990 61 5 759 767 2-s2.0-0025312728 10.1016/0092-8674(90) 90186-I (Pubitemid 20185636)
34. Lipson D., Capelletti M., Yelensky R., Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nature Medicine 2012 18 382 384
35. Sinicrope F. A., Sargent D. J., Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clinical Cancer Research 2012 18 1506 1512
36. Calin G. A., Gafa R., Tibiletti M. G., Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: a study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. International Journal of Cancer 2000 89 230 235 (Pubitemid 30430738)
37. Yashiro M., Hirakawa K., Boland C. R., Mutations in TGFbeta-RII and BAX mediate tumor progression in the later stages of colorectal cancer with microsatellite instability. BMC Cancer 2010 10, article 303 2-s2.0-77953631564 10.1186/1471-2407-10-303
38. Kerber R. A., Neklason D. W., Samowitz W. S., Burt R. W., Frequency of familial colon cancer and hereditary nonpolyposis colorectal cancer (Lynch Syndrome) in a large population database. Familial Cancer 2005 4 3 239 244 2-s2.0-18844392206 10.1007/s10689-005-0657-x (Pubitemid 41242193)
39. Samowitz W. S., Albertsen H., Herrick J., Levin T. R., Sweeney C., Murtaugh M. A., Wolff R. K., Slattery M. L., Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005 129 3 837 845 2-s2.0-24144449572 10.1053/j.gastro.2005.06.020 (Pubitemid 41242676)
40. Jenkins M. A., Hayashi S., O'Shea A. M., Burgart L. J., Smyrk T. C., Shimizu D., Waring P. M., Ruszkiewicz A. R., Pollett A. F., Redston M., Barker M. A., Baron J. A., Casey G. R., Dowty J. G., Giles G. G., Limburg P., Newcomb P., Young J. P., Walsh M. D., Thibodeau S. N., Lindor N. M., LeMarchand L., Gallinger S., Haile R. W., Potter J. D., Hopper J. L., Jass J. R., Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007 133 1 48 56 2-s2.0-34447251079 10.1053/j.gastro.2007.04.044 (Pubitemid 47039240)
41. Parsons M. T., Buchanan D. D., Thompson B., Young J. P., Spurdle A. B., Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. Journal of Medical Genetics 2012 49 151 157
42. Sinicrope F. A., Foster N. R., Thibodeau S. N., Marsoni S., Monges G., Labianca R., Yothers G., Allegra C., Moore M. J., Gallinger S., Sargent D. J., DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. Journal of the National Cancer Institute 2011 103 11 863 875 2-s2.0-79958828886 10.1093/jnci/djr153
43. Sargent D. J., Marsoni S., Monges G., Thibodeau S. N., Labianca R., Hamilton S. R., French A. J., Kabat B., Foster N. R., Torri V., Ribic C., Grothey A., Moore M., Zaniboni A., Seitz J. F., Sinicrope F., Gallinger S., Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. Journal of Clinical Oncology 2010 28 20 3219 3226 2-s2.0-77954748953 10.1200/JCO.2009.27.1825
44. Ribic C. M., Sargent D. J., Moore M. J., Thibodeau S. N., French A. J., Goldberg R. M., Hamilton S. R., Laurent-Puig P., Gryfe R., Shepherd L. E., Tu D., Redston M., Gallinger S., Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. The New England Journal of Medicine 2003 349 3 247 257 2-s2.0-0038002279 10.1056/NEJMoa022289 (Pubitemid 36859476)
45. French A. J., Sargent D. J., Burgart L. J., Foster N. R., Kabat B. F., Goldberg R., Shepherd L., Windschitl H. E., Thibodeau S. N., Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clinical Cancer Research 2008 14 11 3408 3415 2-s2.0-50349091081 10.1158/1078-0432.CCR-07-1489
46. Kim G. P., Colangelo L. H., Wieand H. S., Paik S., Kirsch I. R., Wolmark N., Allegra C. J., Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-national surgical adjuvant breast and bowel project collaborative study. Journal of Clinical Oncology 2007 25 7 767 772 2-s2.0-33947546541 10.1200/JCO.2006.05.8172 (Pubitemid 350002875)
47. Hutchins G., Southward K., Handley K., Magill L., Beaumont C., Stahlschmidt J., Richman S., Chambers P., Seymour M., Kerr D., Gray R., Quirke P., Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. Journal of Clinical Oncology 2011 29 10 1261 1270 2-s2.0-79953856354 10.1200/JCO.2010.30.1366
48. Plaschke J., Preussler M., Ziegler A., Schackert H. K., Aberrant protein expression and frequent allelic loss of MSH3 in colorectal cancer with low-level microsatellite instability. The International Journal of Colorectal Disease 2012 27 7 911 919
49. Pinheiro M., Ahlquist T., Danielsen S. A., Lind G. E., Veiga I., Pinto C., Costa V. L., Afonso L., Sousa O., Fragoso M., Santos L., Henrique R., Lopes P., Lopes C., Lothe R. A., Teixeira M. R., Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. BMC Cancer 2010 10, article 587 2-s2.0-77958501860 10.1186/1471-2407-10-587
50. Hong S. P., Min B. S., Kim T. I., Cheon J. H., Kim N. K., Kim H., Kim: W. H., The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. European Journal of Cancer 2012 48 8 1235 1243
51. Sargent D. J., Marsoni S., Monges G., Thibodeau S. N., Labianca R., Hamilton S. R., French A. J., Kabat B., Foster N. R., Torri V., Ribic C., Grothey A., Moore M., Zaniboni A., Seitz J. F., Sinicrope F., Gallinger S., Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. Journal of Clinical Oncology 2010 28 20 3219 3226 2-s2.0-77954748953 10.1200/JCO.2009.27.1825
52. Min B. H., Bae J. M., Lee E. J., Yu H. S., Kim Y. H., Chang D. K., Kim H. C., Park C. K., Lee S. H., Kim K. M., Kang G. H., The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011 11, article 344 2-s2.0-79961137937 10.1186/1471-2407-11-344
53. Jover R., Nguyen T., Prezcarbonell L., Zapater P., Pay A., Alenda C., Rojas E., Cubiella J., Balaguer F., Morillas J. D., Clofent J., Bujanda L., Re J. M., Bessa X., Xicola R. M., Nicolsprez D., Castells A., Andreu M., Llor X., Boland C. R., Goel A., 5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011 140 4 1174 1181 2-s2.0-79953217628 10.1053/j.gastro.2010. 12.035
54. Kim J. E., Hong Y. S., Ryu M. H., Lee J. L., Chang H. M., Lim S. B., Kim J. H., Jang S. J., Kim M. J., Yu C. S., Kang Y. K., Kim J. C., Kim T. W., Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer. Cancer Science 2011 102 9 1706 1711 2-s2.0-79960159733 10.1111/j.1349-7006.2011.02009.x
55. Bertagnolli M. M., Niedzwiecki D., Compton C. C., Hahn H. P., Hall M., Damas B., Jewell S. D., Mayer R. J., Goldberg R. M., Saltz L. B., Warren R. S., Redston M., Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. Journal of Clinical Oncology 2009 27 11 1814 1821 2-s2.0-64649096900 10.1200/JCO.2008.18.2071
56. Kim S. T., Lee J., Park S. H., Park J. O., Lim H. Y., Kang W. K., Kim J. Y., Kim Y. H., Chang D. K., Rhee P. L., Kim D. S., Yun H., Cho Y. B., Kim H. C., Yun S. H., Lee W. Y., Chun H. K., Park Y. S., Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemotherapy and Pharmacology 2010 66 4 659 667 2-s2.0-77955872994 10.1007/s00280-009-1206-3
57. Kim S. T., Lee J., Park S. H., Park J. O., Lim H. Y., Kang W. K., Kim J. Y., Kim Y. H., Chang D. K., Rhee P. L., Kim D. S., Yun H., Cho Y. B., Kim H. C., Yun S. H., Chun H. K., Lee W. Y., Park Y. S., The effect of DNA mismatch repair (MMR) status on oxaliplatinbased first-line chemotherapy as in recurrent or metastatic colon cancer. Medical Oncology 2010 27 4 1277 1285 2-s2.0-79951768387 10.1007/s12032-009-9374-x
58. Price T. J., Hardingham J. E., Lee C. K., Weickhardt A., Townsend A. R., Wrin J. W., Chua A., Shivasami A., Cummins M. M., Murone C., Tebbutt N. C., Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. Journal of Clinical Oncology 2011 29 19 2675 2682 2-s2.0-79960149283 10.1200/JCO.2010.34.5520
59. Vaughn C. P., Zobell S. D., Furtado L. V., Baker C. L., Samowitz W. S., Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes and Cancer 2011 50 5 307 312 2-s2.0-79952392909 10.1002/gcc.20854
60. Karapetis C. S., Khambata-Ford S., Jonker D. J., O'Callaghan C. J., Tu D., Tebbutt N. C., Simes R. J., Chalchal H., Shapiro J. D., Robitaille S., Price T. J., Shepherd L., Au H. J., Langer C., Moore M. J., Zalcberg J. R., K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine 2008 359 17 1757 1765 2-s2.0-54949085398 10.1056/NEJMoa0804385
61. Amado R. G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D. J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S. D., Chang D. D., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008 26 10 1626 1634 2-s2.0-42649145667 10.1200/JCO.2007.14.7116
62. Douillard J. Y., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., Humblet Y., Bodoky G., Cunningham D., Jassem J., Rivera F., Kocákova I., Ruff P., Basiska-Morawiec M., Šmakal M., Canon J. L., Rother M., Oliner K. S., Wolf M., Gansert J., Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME Study. Journal of Clinical Oncology 2010 28 31 4697 4705 2-s2.0-78149250536 10.1200/JCO.2009.27.4860
63. Derer S., Berger S., Schlaeth M., Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPbeta-dependent suppression of EGFR expression. Neoplasia 2012 14 190 205
64. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K. T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., Di Fiore F., Gangloff A. O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T. P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet Oncology 2010 11 8 753 762 2-s2.0-77955277111 10.1016/S1470-2045(10)70130-3
65. Ogino S., Shima K., Meyerhardt J. A., Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB, 89803. Clinical Cancer Research 2012 18 890 900
66. Liao X., Morikawa T., Lochhead P., Imamura Y., Kuchiba A., Yamauchi M., Nosho K., Qian Z. R., Nishihara R., Meyerhardt J. A., Fuchs C. S., Ogino S., Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clinical Cancer Research 2012 18 2257 2268
67. Janku F., Lee J. J., Tsimberidou A. M., Hong D. S., Naing A., Falchook G. S., Fu S., Luthra R., Garrido-Laguna I., Kurzrock R., PIK3CA mutations frequently coexist with ras and braf mutations in patients with advanced cancers. PLoS ONE 2011 6 7, article e22769 2-s2.0-79960927451 10.1371/journal.pone.0022769
68. Velho S., Oliveira C., Ferreira A., Ferreira A. C., Suriano G., Schwartz S., Duval A., Carneiro F., Machado J. C., Hamelin R., Seruca R., The prevalence of PIK3CA mutations in gastric and colon cancer. European Journal of Cancer 2005 41 11 1649 1654 2-s2.0-22144452507 10.1016/j.ejca.2005.04.022 (Pubitemid 40981849)
69. Irahara N., Baba Y., Nosho K., Shima K., Yan L., Dias-Santagata D., Iafrate A. J., Fuchs C. S., Haigis K. M., Ogino S., NRAS mutations are rare in colorectal cancer. Diagnostic Molecular Pathology 2010 19 3 157 163 2-s2.0-77956238031 10.1097/PDM.0b013e3181c93fd1
70. Scartozzi M., Mandolesi A., Giampieri R., Bittoni A., Pierantoni C., Zaniboni A., Galizia E., Giustini L., Silva R. R., Bisonni R., Berardi R., Biscotti T., Biagetti S., Bearzi I., Cascinu S., The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist 2011 16 1 53 60 2-s2.0-79952607191 10.1634/theoncologist.2010-0119
71. Inno A., Di Salvatore M., Cenci T., Martini M., Orlandi A., Strippoli A., Ferrara A. M., Bagala C., Cassano A., Larocca L. M., Barone C., Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clinical Colorectal Cancer 2011 10 325 332
72. Bokemeyer C., Cutsem E. V., Rougier P., Ciardiello F., Heeger S., Schlichting M., Celik I., Kohne C. H., Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. European Journal of Cancer 2012 48 10 1466 1475
73. Yokota T., Ura T., Shibata N., Takahari D., Shitara K., Nomura M., Kondo C., Mizota A., Utsunomiya S., Muro K., Yatabe Y., BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. British Journal of Cancer 2011 104 5 856 862 2-s2.0-79952282994 10.1038/bjc.2011.19
74. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A., Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Journal of Clinical Oncology 2008 26 35 5705 5712 2-s2.0-57449095367 10.1200/JCO.2008.18.0786
75. Laurent-Puig P., Cayre A., Manceau G., Buc E., Bachet J. B., Lecomte T., Rougier P., Lievre A., Landi B., Boige V., Ducreux M., Ychou M., Bibeau F., Bouché O., Reid J., Stone S., Penault-Llorca F., Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Journal of Clinical Oncology 2009 27 35 5924 5930 2-s2.0-73349094741 10.1200/JCO.2008.21.6796
76. Maughan T. S., Adams R. A., Smith C. G., Meade A. M., Seymour M. T., Wilson R. H., Idziaszczyk S., Harris R., Fisher D., Kenny S. L., Kay E., Mitchell J. K., Madi A., Jasani B., James M. D., Bridgewater J., Kennedy M. J., Claes B., Lambrechts D., Kaplan R., Cheadle J. P., Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet 2011 377 9783 2103 2114 2-s2.0-79959337678 10.1016/S0140-6736(11)60613-2
77. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R. L., Bardelli A., Bernards R., Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012 483 100 103
78. Dal Lago L., D'Hondt V., Awada A., Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008 13 8 845 858 2-s2.0-51049098909 10.1634/theoncologist.2007-0233
79. Whitehall V. L., Rickman C., Bond C. E., Ramsnes I., Greco S. A., Umapathy A., McKeone D., Faleiro R. J., Buttenshaw R. L., Worthley D. L., Nayler S., Zhao Z. Z., Montgomery G. W., Mallitt K. A., Jass J. R., Matsubara N., Notohara K., Ishii T., Leggett B. A., Oncogenic PIK3CA mutations in colorectal cancers and polyps. International Journal of Cancer 2012 131 4 813 820
80. Janku F., Tsimberidou A. M., Garrido-Laguna I., Wang X., Luthra R., Hong D. S., Naing A., Falchook G. S., Moroney J. W., Piha-Paul S. A., Wheler J. J., Moulder S. L., Fu S., Kurzrock R., PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Molecular Cancer Therapeutics 2011 10 3 558 565 2-s2.0-79952690921 10.1158/1535-7163.MCT-10-0994
81. Young A., Lyons J., Miller A. L., Phan V. T., Alarcón I. R., McCormick F., Ras signaling and therapies. Advances in Cancer Research 2009 102 1 17 2-s2.0-70349252174 10.1016/S0065-230X(09)02001-6
82. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
83. Prabhudesai S. G., Rekhraj S., Roberts G., Darzi A. W., Ziprin P., Apoptosis and chemo-resistance in colorectal cancer. Journal of Surgical Oncology 2007 96 1 77 88 2-s2.0-34347358420 10.1002/jso.20785 (Pubitemid 47015454)
84. Wilson T. R., McLaughlin K. M., McEwan M., Sakai H., Rogers K. M. A., Redmond K. M., Johnston P. G., Longley D. B., c-FLIP: a key regulator of colorectal cancer cell death. Cancer Research 2007 67 12 5754 5762 2-s2.0-34250844497 10.1158/0008-5472.CAN-06-3585 (Pubitemid 46985008)
85. Longley D. B., Wilson T. R., McEwan M., Allen W. L., McDermott U., Galligan L., Johnston P. G., c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006 25 6 838 848 2-s2.0-32544438637 10.1038/sj.onc.1209122 (Pubitemid 43237702)
86. Anguiano-Hernandez Y. M., Chartier A., Huerta S., Smac/DIABLO and colon cancer. Anti-Cancer Agents in Medicinal Chemistry 2007 7 4 467 473 2-s2.0-34547119284 10.2174/187152007781058631 (Pubitemid 47099052)
87. Karasawa H., Miura K., Fujibuchi W., Ishida K., Kaneko N., Kinouchi M., Okabe M., Ando T., Murata Y., Sasaki H., Takami K., Yamamura A., Shibata C., Sasaki I., Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Science 2009 100 5 903 913 2-s2.0-65349194435 10.1111/j.1349-7006.2009.01112.x
88. Zhang Y. L., Pang L. Q., Wu Y., Wang X. Y., Wang C. Q., Fan Y., Significance of Bcl-xL in human colon carcinoma. World Journal of Gastroenterology 2008 14 19 3069 3073 2-s2.0-48049083344 10.3748/wjg.14.3069
89. Pan Y., Xu R., Peach M., Huang C. P., Branstetter D., Novotny W., Herbst R. S., Eckhardt S. G., Holland P. M., Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. British Journal of Cancer 2011 105 12 1830 1838
90. Gandhi L., Camidge D. R., De Oliveira M. R., Bonomi P., Gandara D., Khaira D., Hann C. L., McKeegan E. M., Litvinovich E., Hemken P. M., Dive C., Enschede S. H., Nolan C., Chiu Y. L., Busman T., Xiong H., Krivoshik A. P., Humerickhouse R., Shapiro G. I., Rudin C. M., Phase I study of navitoclax (ABT-263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. Journal of Clinical Oncology 2011 29 7 909 916 2-s2.0-79952291173 10.1200/JCO.2010.31.6208
91. Leber B., Geng F., Kale J., Andrews D. W., Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Reviews in Molecular Medicine 2010 12, article e28 2-s2.0-79952112980
92. Letai A. G., Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nature Reviews Cancer 2008 8 2 121 132 2-s2.0-38549145044 10.1038/nrc2297 (Pubitemid 351161322)
93. O'Mahony D., Morris J. C., Quinn C., Gao W., Wilson W. H., Gause B., Pittaluga S., Neelapu S., Brown M., Fleisher T. A., Gulley J. L., Schlom J., Nussenblatt R., Albert P., Davis T. A., Lowy I., Petrus M., Waldmann T. A., Janik J. E., A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clinical Cancer Research 2007 13 3 958 964 2-s2.0-33847407907 10.1158/1078-0432.CCR-06-1974 (Pubitemid 46340373)
94. Rothwell P. M., Wilson M., Price J. F., Belch J. F., Meade T. W., Mehta Z., Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012 379 1591 1601
95. Sylvester B. E., Huo D., Khramtsov A., Zhang J., Smalling R. V., Olugbile S., Polite B. N., Olopade O. I., Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clinical Cancer Research 2012 18 350 359
96. Landsbergen K. M., Prins J. B., Brunner H. G., van Duijvendijk P., Nagengast F. M., van Krieken J. H., Ligtenberg M., Hoogerbrugge: N., Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist's initiative. Familial Cancer 2012 11 2 259 267
97. Gerlinger M., Rowan A. J., Horswell S., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine 2012 366 883 892
98. Lee A. J., Swanton C., Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics. Biochemical Pharmacology 2012 83 1013 1020
99. Oltedal S., Aasprong O. G., Moller J. H., Korner H., Gilje B., Tjensvoll K., Birkemeyer E. M., Heikkilä R., Smaaland R., Nordgård O., Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. International Journal of Colorectal Disease 2011 26 1271 1277 2-s2.0-79955833152 10.1007/s00384-011-1233-5
100. Balschun K., Haag J., Wenke A. K., von Schonfels W., Schwarz N. T., Rocken C., KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. Journal of Molecular Diagnostics 2011 13 436 445
101. Maheswaran S., Sequist L. V., Nagrath S., Ulkus L., Brannigan B., Collura C. V., Inserra E., Diederichs S., Iafrate A. J., Bell D. W., Digumarthy S., Muzikansky A., Irimia D., Settleman J., Tompkins R. G., Lynch T. J., Toner M., Haber D. A., Detection of mutations in EGFR in circulating lung-cancer cells. The New England Journal of Medicine 2008 359 4 366 377 2-s2.0-47949114668 10.1056/NEJMoa0800668
102. Booth C. M., Calvert A. H., Giaccone G., Lobbezoo M. W., Seymour L. K., Eisenhauer E. A., Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). European Journal of Cancer 2008 44 1 19 24 2-s2.0-37149030424 10.1016/j.ejca.2007.07.034 (Pubitemid 350256933)
103. Ochenduszko S. L., Krzemieniecki K., Targeted therapy in advanced colorectal cancer: more data, more questions. Anti-Cancer Drugs 2010 21 8 737 748 2-s2.0-77955230057 10.1097/CAD.0b013e32833cfc99
104. Punt C. J. A., Tol J., More is less-combining targeted therapies in metastatic colorectal cancer. Nature Reviews Clinical Oncology 2009 6 12 731 733 2-s2.0-75649085336 10.1038/nrclinonc.2009.168
105. Adams R. A., Meade A. M., Madi A., Fisher D., Kay E., Kenny S., Kaplan R. S., Maughan T. S., Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. British Journal of Cancer 2009 100 2 251 258 2-s2.0-58749087713 10.1038/sj.bjc.6604877
106. Okines A. F. C., Ashley S. E., Cunningham D., Oates J., Turner A., Webb J., Saffery C., Chua Y. J., Chau I., Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. Journal of Clinical Oncology 2010 28 25 3945 3950 2-s2.0-77957552916 10.1200/JCO.2010.29.2847
107. Larson E. B., Ellsworth A. J., Oas J., Randomized clinical trials in single patients during a 2-year period. Journal of the American Medical Association 1993 270 22 2708 2712 2-s2.0-0027422209 10.1001/jama.270.22.2708 (Pubitemid 23350968)
108. Lillie E. O., Patay B., Diamant J., Issell B., Topol E. J., Schork N. J., The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Personalized Medicine 2011 8 2 161 173 2-s2.0-79952590347 10.2217/pme.11.7
109. Von Hoff D. D., Stephenson J. J., Rosen P., Loesch D. M., Borad M. J., Anthony S., Jameson G., Brown S., Cantafio N., Richards D. A., Fitch T. R., Wasserman E., Fernandez C., Green S., Sutherland W., Bittner M., Alarcon A., Mallery D., Penny R., Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. Journal of Clinical Oncology 2010 28 33 4877 4883 2-s2.0-79951906119 10.1200/JCO.2009.26.5983
110. Doroshow J. H., Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors? Journal of Clinical Oncology 2010 28 33 4869 4871 2-s2.0-79951897927 10.1200/JCO.2010.31.1472